This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
This activity is designed to update physicians on the data that have been recently presented in Orlando so that they can assess and prepare to apply these findings to their clinical practice to improve patient care.
Instructions For This Activity & Receiving Credit
This educational activity is directed toward medical oncologists/hematologists and fellows who treat patients with myeloproliferative neoplasms. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of myeloproliferative neoplasms will be invited to participate.
Ruben Mesa, MD, FACP
Chair, Division of Hematology & Medical Oncology
Deputy Director, Mayo Clinic Cancer Center
Chair, Arizona Cancer Coalition
Professor of Medicine
Mayo Clinic Cancer Center
Disclosure: Grant/Research Support: Incyte, Gilead, CTI, Genentech, NS Pharma, Inc., Promedior Consultant: Novartis
Michael Mauro, MD
Leader, Myeloproliferative Neoplasms Program
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosure: Grant/Research Support: Novartis
It is the policy of PER® to ensure the fair balance, independence, objectivity, and scientific objectivity in all of our CME activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians' Education Resource®, LLC, or any of the companies that provided commercial support for this activity.
Oncology Briefings™: Updates in Therapeutic Options and Approaches for Tenosynovial Giant Cell Tumors
Apr 28, 2018
April 28, 2018
New York, NY